Characterization of anti-HCV antibodies in IL-10-treated patients

Viral Immunology

Volumn 23, Issue 4, 2010, Pages 359-368

  Eksioglu, Erika A ^a   Bess, Jennifer ^a   Jones, Graham ^a   Dettloff, Jennifer ^a   Dangmeon, Parinda ^a   Dong, Hui Jia ^a   Zhu, Haizhen ^b   Firpi, Roberto ^a   Xu, Yiling ^a   Nelson, David R ^a   Liu, Chen ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HUNAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 10;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; CELL LINE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10; MALE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

HEPATITIS C VIRUS;

EID: 77955887309     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0095     Document Type: Article

References (64)

1. Gerlach JT, Diepolder HM, Zachoval R, et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
2. Srivastava IK, Ulmer JB, and Barnett SW: Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccine 2005;1:45-60.
3. Barth H, Liang TJ, and Baumert TF: Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006;44:527-535.
4. Netski DM, Mosbruger T, Depla E, et al.: Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005;41:667-675.
5. Zeisel MB, Cosset FL, and Baumert TF: Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 2008;48:299-307.
6. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, and Rennick DM: Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991;173:507-510.
7. Moore KW, de Waal Malefyt R, Coffman RL, and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
8. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, and de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
9. Ye Z, Huang H, Hao S, Xu S, Yu H, Van Den Hurk S, and Xiang J: IL-10 has a distinct immunoregulatory effect on naive and active T cell subsets. J Interferon Cytokine Res 2007;27:1031-1038.
10. Minter RM, Ferry MA, Rectenwald JE, et al.: Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. Proc Natl Acad Sci USA 2001;98:277-282.
11. Weiss E, Mamelak AJ, La Morgia S, Wang B, Feliciani C, Tulli A, and Sauder DN: The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J Am Acad Dermatol 2004;50:657-675; quiz 676-1658
12. Napoli J, Bishop GA, McGuinness PH, Painter DM, and McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-765.
13. Nelson DR, and Lau JY: Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection. Clin Liver Dis 1997;1:515-528, v.
14. Nelson DR, Lauwers GY, Lau JY, and Davis GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-660.
15. Nelson DR, Tu Z, Soldevila-Pico C, et al.: Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38: 859-868.
16. Farci P, Alter HJ, Wong DC, et al.: Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91: 7792-7796.
17. Farci P, Shimoda A, Wong D, et al.: Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-15399. (Pubitemid 27009611)
18. Rosa D, Campagnoli S, Moretto C, et al.: A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996;93: 1759-1763.
19. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, and Yoshikura H: Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-1500.
20. Fournier C, Duverlie G, Francois C, et al.: A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J 2007;4:35.
21. Cai Z, Zhang C, Chang KS, et al.: Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNAtransfected human hepatoma cells. J Virol 2005;79:13963-13973.
22. Wakita T, Pietschmann T, Kato T, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
23. Zhu H, Dong H, Eksioglu E, et al.: Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007;133:1649-1659.
24. Lavillette D, Morice Y, Germanidis G, et al.: Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005;79:6023-6034.
25. Bartosch B, Verney G, Dreux M, et al.: An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217-8229.
26. Meunier JC, Engle RE, Faulk K, et al.: Evidence for crossgenotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005;102:4560-4565.
27. Haberstroh A, Schnober EK, Zeisel MB, et al.: Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008;135:1719-1728 e1711.
28. Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, and Baumert TF: Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007;13: 4824-4830.
29. Recher M, Hunziker L, Ciurea A, Harris N, and Lang KS: Public, private and non-specific antibodies induced by noncytopathic viral infections. Curr Opin Microbiol 2004;7: 426-433.
30. Pestka JM, Zeisel MB, Blaser E, et al.: Rapid induction of virus-neutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-6030.
31. Basu A, Kanda T, Beyene A, Saito K, Meyer K, and Ray R: Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 2007;81:3933-3941.
32. Pawlotsky JM: Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004;12: 96-102.
33. Yu MY, Bartosch B, Zhang P, et al.: Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004;101:7705-7710.
34. Frost SD, Wrin T, Smith DM, et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005;102:18514-18519. (Pubitemid 43011257)
35. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, and McKeating JA: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132: 667-678.
36. Keck ZY, Xia J, Cai Z, et al.: Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 2007;81:1043-1047.
37. Timpe JM, Stamataki Z, Jennings A, et al.: Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24.
38. Houghton M, and Abrignani S: Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-966.
39. Law M, Maruyama T, Lewis J, et al.: Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-27.
40. Perotti M, Mancini N, Diotti RA, et al.: Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82:1047-1052.
41. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, and Persson MA: Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci USA 2007;104:16269-16274.
42. Tan SL, Pause A, Shi Y, and Sonenberg N: Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov 2002;1:867-881.
43. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, and Nelson DR: An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004;40:1062-1071.
44. Gremion C, and Cerny A: Hepatitis C virus and the immune system: a concise review. Rev Med Virol 2005;15:235-268.
45. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, and Oldstone MB: Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-1309.
46. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, and von Herrath MG: Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006;203:2461-2472.
47. Thimme R, and Opitz OG: Interleukin-10 and viral clearance: translation to viral hepatitis. Gastroenterology 2007; 132:2611-2613.
48. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, and Spengler U: HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol 2002;8:562-566.
49. Asadullah K, Sterry W, and Volk HD: Interleukin-10 therapy- review of a new approach. Pharmacol Rev 2003;55: 241-269.
50. Fearon DT, and Carter RH: The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-149.
51. Levy S, Todd SC, and Maecker HT: CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89-109.
52. Machida K, Kondo Y, Huang JY, et al.: Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol 2008;82:6711-6720.
53. Cocquerel L, Kuo CC, Dubuisson J, and Levy S: CD81- dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 2003;77:10677-10683.
54. Nakajima H, Cocquerel L, Kiyokawa N, Fujimoto J, and Levy S: Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop. Biochem Biophys Res Commun 2005;328:1091-1100.
55. Petracca R, Falugi F, Galli G, et al.: Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000;74:4824-4830.
56. Pileri P, Uematsu Y, Campagnoli S, et al.: Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
57. Bartosch B, Vitelli A, Granier C, et al.: Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624-41630.
58. Foy E, Li K, Sumpter R Jr, et al.: Control of antiviral defenses through hepatitis C virus disruption of retinoic acidinducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102:2986-2991.
59. Tirado SM, and Yoon KJ: Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003;16:69-86.
60. Burioni R, Mancini N, Canducci F, et al.: Humoral immune response against hepatitis C virus. J Biol Regul Homeost Agents 2003;17:125-127.
61. Burioni R, Mancini N, Carletti S, et al.: Cross-reactive pseudovirus- neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 2004;327:242-248.
62. Mancini N, Canducci F, Carletti S, et al.: Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies. J Biol Regul Homeost Agents 2003;17:183-187.
63. Tarr AW, Owsianka AM, Timms JM, et al.: Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006;43:592-601.
64. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, and Feinstone SM: Hepatitis C virus epitopespecific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 2007;104:8449-8454.